A Study to Evaluate Mavacamten Impact on Myocardial Structure in Participants With Symptomatic Obstructive Hypertrophic Cardiomyopathy

PHASE4Active, not recruitingINTERVENTIONAL
Enrollment

63

Participants

Timeline

Start Date

January 24, 2024

Primary Completion Date

July 9, 2026

Study Completion Date

July 9, 2026

Conditions
Cardiomyopathy, Hypertrophic
Interventions
DRUG

Mavacamten

Specified dose on specified days

Trial Locations (23)

1093

Local Institution - 0076, Ciudad Autónoma de Buenos Aires

1199

Local Institution - 0080, Buenos Aires

1205

Local Institution - 0061, Geneva

2050

Local Institution - 0015, Camperdown

3004

Local Institution - 0005, Melbourne

4032

Local Institution - 0085, Chermside

6000

Local Institution - 0058, Lucerne

6900

Local Institution - 0029, Lugano

8091

Local Institution - 0024, Zürich (de)

30309

Local Institution - 0003, Atlanta

44106

Local Institution - 0090, Cleveland

77030

Local Institution - 0017, Houston

90048-1804

Local Institution - 0087, West Hollywood

02114

Local Institution - 0093, Boston

15212-4756

Local Institution - 0086, Pittsburgh

84107-5701

Local Institution - 0035, Murray

C1428ART

Local Institution - 0075, Ciudad Autónoma de Buenos Aires

B1629ODT

Local Institution - 0079, Pilar

X5021FPQ

Local Institution - 0077, Córdoba

S2000GAP

Local Institution - 0074, Rosario

H1T 1C8

Local Institution - 0001, Montreal

G1V 4G5

Local Institution - 0068, Québec

LS1 3EX

Local Institution - 0025, Leeds

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT06112743 - A Study to Evaluate Mavacamten Impact on Myocardial Structure in Participants With Symptomatic Obstructive Hypertrophic Cardiomyopathy | Biotech Hunter | Biotech Hunter